02:16 , Nov 12, 2014 |  BC Extra  |  Company News

Ascletis gets China license for Presidio HCV candidate

Presidio Pharmaceuticals Inc. (San Francisco, Calif.) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights to HCV candidate PPI-668 in China, Taiwan, Hong Kong and Macau. Presidio received an undisclosed upfront payment...
07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas and...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Ascletis, J&J deal

Johnson & Johnson's Janssen R&D Ireland unit granted Ascletis exclusive rights to develop and commercialize Janssen's HIV compound TMC310911 in China. J&J is eligible for undisclosed royalties based on Chinese sales of the HIV...
07:00 , Apr 15, 2013 |  BioCentury  |  Strategy

IP armamentarium

With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Alnylam, Tekmira Pharmaceuticals Inc. deal

Alnylam and Tekmira agreed to a new deal and will settle all litigation between the partners, including a suit related to Tekmira's lipid nanoparticle (LNP) siRNA delivery technology. Alnylam will pay Tekmira $65 million, including...
08:00 , Nov 19, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.19 (47%) to $2.44 on Friday, which translates to a loss in market cap of $391.4 million, after FDA's Vaccines and Related Biological Products Advisory Committee voted 8-5 with...
02:28 , Nov 14, 2012 |  BC Extra  |  Company News

Alnylam, Tekmira restructure partnership, settle litigation

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) agreed to a new deal that will settle all litigation between the partners, including a suit related to Tekmira's lipid nanoparticle (LNP) siRNA delivery technology....
07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Ascletis: Cash for China deals

While Ascletis Pharmaceuticals Co. Ltd. aspires to discover its own drugs, it is employing a two-pronged strategy that includes in-licensing clinical candidates for the Chinese market. Its first external compound comes from Alnylam Pharmaceuticals Inc. According...
07:00 , Jul 16, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioMimetic Therapeutics Inc. (NASDAQ:BMTI) gained $0.66 (24%) to $3.46 on Tuesday after submitting to FDA an amendment to the PMA for Augment Bone Graft, which is under review for use as an alternative to...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Alnylam, Ascletis deal

Ascletis received exclusive rights in China to develop and commercialize Alnylam's RNAi therapeutic ALN-VSP, which completed a Phase I trial for liver cancer. ALN-VSP is a lipid nanoparticle formulation of two short interfering RNAs...